Document Detail


ACOG Committee Opinion. Number 258, September 2001. Fetal pulse oximetry.
MedLine Citation:
PMID:  11547792     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The U.S. Food and Drug Administration recently approved the marketing of the Nellcor N-400 Fetal Oxygen Saturation Monitoring System, a fetal pulse oximeter. The American College of Obstetricians and Gynecologists Committee on Obstetric Practice cannot endorse the adoption of this device in clinical practice at this time because of concerns that its introduction could further escalate the cost of medical care without necessarily improving clinical outcome. The committee recommends that prospective randomized clinical trials be conducted to evaluate the clinical use of this new technology in conjunction with fetal well-being assessment.
Authors:
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Obstetrics and gynecology     Volume:  98     ISSN:  0029-7844     ISO Abbreviation:  Obstet Gynecol     Publication Date:  2001 Sep 
Date Detail:
Created Date:  2001-09-06     Completed Date:  2001-09-20     Revised Date:  2009-10-26    
Medline Journal Info:
Nlm Unique ID:  0401101     Medline TA:  Obstet Gynecol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  523-4     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Device Approval*
Fetal Monitoring / instrumentation*
Humans
Oximetry / instrumentation*
United States
United States Food and Drug Administration
Comments/Corrections
Comment In:
Obstet Gynecol. 2002 Mar;99(3):514-6   [PMID:  11864685 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of sympathetic reinnervation on cardiac performance after heart transplantation.
Next Document:  ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 30, Se...